Understand this story
On November 17, Demis Hassabis announced that Isomorphic Labs had secured funding to accelerate its goal of tackling all diseases, saying that the team is using AI to redesign drugs from first principles in order to shorten drug development timelines and reduce costs. The structured key facts list the amount as $5 billion, but the representative evidence from the same event and another report both list it as $500 million, creating a discrepancy in the available materials. Later that day, Peter Yang reposted the announcement and expressed his support, saying that Demis Hassabis and his team were the right people to tackle disease.
AI-generated from public reports
Latest development · Report
Isomorphic Labs Completes $5 Billion Series C Funding Round to Advance AI Drug Discovery InfrastructureDevelopments
2 confirmed developments
Demis Hassabis announces $5 billion funding for Isomorphic Labs
Source:Demis HassabisPeter Yang says Demis Hassabis is the right person to cure diseases
Source:Peter Yang
Reports and discussion timeline
Browse reports and discussion by time. Their evidence levels remain distinct.
Nov 19
Phoenix Technology
Isomorphic Labs Completes $5 Billion Series C Funding Round to Advance AI Drug Discovery Infrastructure
Isomorphic Labs announced on November 17 that it had completed a $5 billion Series C funding round, which will be used to advance foundational simulation models, expand its pipeline of drug candidates, and build AI-driven bioengineering infrastructure. A 2024 BCG report said that AI-generated drug molecules have an 80%-90% success rate in Phase I clinical trials, compared with the historical industry average of 40%-65%. Soochow Securities believes that the AI drug discovery technology stack is shifting from standalone algorithmic tools to a multimodal technology matrix.
Nov 18
Dave ShapiroRelated discussion
Dave Shapiro joined this discussion
This post contributes to heat; it is not a formal report or confirmed fact.
Wallstreetcn
Isomorphic Labs Completes $5 Billion Series C Funding, Doubling Its Previous Round
Isomorphic Labs, Alphabet's AI drug discovery company, announced on November 17 that it had completed a $5 billion Series C funding round, co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and Alphabet. This round comes about six months after its $2.1 billion Series B funding in May of this year, with the scale more than doubling; the funds will be used to advance AI-driven new drug design and R&D. According to Dealroom data, AI drug discovery startups have raised a cumulative $23.2 billion in 2026.
Phoenix Technology
Google-affiliated AI drug discovery company Isomorphic Labs completes $5 billion Series C funding
Google-affiliated AI drug discovery company Isomorphic Labs announced the completion of a $5 billion Series C funding round, co-led by Greenoaks and Sequoia Capital, with Alphabet continuing to invest on a large scale, setting a new global record for a single funding round in the AI drug discovery field. The company's cumulative publicly disclosed funding has reached $7.7 billion, and its proprietary drug design engine IsoDDE combines simulation models and agents to advance multiple candidate drug pipelines. Hassabis previously stated that the first clinical trials are expected to begin before the end of 2026, a timeline that has been delayed from the original target of the end of 2025.
cnBeta
Isomorphic Labs Secures Largest Single-Round Financing in AI Pharma, Total Funding Reaches $7.7 Billion
Google-affiliated AI pharma company Isomorphic Labs has completed a new funding round, setting a new global record for the largest single-round financing in the AI pharma sector, with total publicly disclosed funding reaching $7.7 billion. Founded by Demis Hassabis, the company's core technologies are the drug design engine IsoDDE and a proprietary Agent for exploring complex biological systems, and it has established R&D collaborations with pharmaceutical companies including Novartis, Eli Lilly, and Johnson & Johnson. In January this year, Hassabis said he expected to launch the first clinical trials before the end of 2026, a delay from the previous target of the end of 2025.
cnBetaRelated discussion
cnBeta joined this discussion
This post contributes to heat; it is not a formal report or confirmed fact.
Yicai
Google-backed Isomorphic Labs completes $5 billion Series C funding, setting a record for a single round in AI drug discovery
Google-backed AI drug discovery company Isomorphic Labs announced the completion of a $5 billion Series C funding round, co-led by Greenoaks and Sequoia Capital, with participation from new investors including a16z, while Alphabet continues to invest on a large scale, setting a new global record for the size of a single funding round in the AI drug discovery field. The company's core technology is the drug design engine IsoDDE, which integrates foundational simulation AI models with proprietary Agent, and it has established R&D collaborations with pharmaceutical companies such as Novartis, Eli Lilly, and Johnson & Johnson, with its internal oncology and immunology programs achieving preclinical results. Hassabis said in January this year that he expected to launch the first clinical trials before the end of 2026, a delay from the previous target of the end of 2025; the company currently has no drugs on the market.
YicaiRelated discussion
Yicai joined this discussion
This post contributes to heat; it is not a formal report or confirmed fact.
Sina Tech
Google-affiliated AI drug discovery company Isomorphic Labs completes $5 billion Series C funding
Isomorphic Labs announced on November 17 that it had completed a $5 billion Series C funding round, co-led by Greenoaks and Sequoia Capital, with new investors including a16z participating, Alphabet continuing to invest on a large scale, and existing investors including Temasek, Thrive Capital, and MGX also taking part. This round sets a new global record for the scale of a single funding round in the AI drug discovery field, coming just half a year after its $2.1 billion Series B round in May this year; the company's cumulative publicly disclosed funding has now reached $7.7 billion. The company's core technology is the drug design engine IsoDDE, which integrates foundational simulation AI models with proprietary Agents, and it has established R&D collaborations with pharmaceutical companies such as Novartis, Eli Lilly, and Johnson & Johnson; Hassabis said in January this year that he expected the first batch of clinical trials to begin before the end of 2026, a delay from the previous target of the end of 2025.
Cailian Press
Isomorphic Labs Completes $5 Billion Series C Funding, Setting a New Record for a Single AI Pharma Financing Round
Isomorphic Labs, the AI drug discovery company under Alphabet, has completed a $5 billion Series C funding round, co-led by Greenoaks and Sequoia Capital, with a16z newly participating and Alphabet continuing to make a large additional investment, setting a new global record for a single AI pharma financing round. The company's CEO is Demis Hassabis, co-founder of DeepMind and winner of the 2024 Nobel Prize in Chemistry. It has developed its own AI drug design engine, IsoDDE, pursuing an end-to-end generative drug R&D route combining large models with intelligent Agents. Currently, the company has no candidate drug in clinical trials; this round of funding will go toward iterating the IsoDDE model, advancing internal proprietary pipelines, and building global infrastructure.
Cailian PressRelated discussion
Cailian Press joined this discussion
This post contributes to heat; it is not a formal report or confirmed fact.
East Money
Isomorphic Labs Completes $5 Billion Series C Funding, Setting a New Record for a Single AI Drug Discovery Financing Round
Isomorphic Labs, an AI drug discovery company under Alphabet, announced on November 17 that it had completed a $5 billion Series C funding round, co-led by Greenoaks and Sequoia Capital, with a16z newly participating, and with all existing shareholders including Alphabet, Thrive Capital, MGX, GV, Temasek, and the UK Sovereign AI Fund following on, setting a new global record for a single AI drug discovery financing round. Spun out of Google DeepMind, the company has Demis Hassabis as CEO and has developed its own AI drug design engine, IsoDDE, pursuing an end-to-end generative drug discovery approach combining large models and agents. Currently, it has no candidate drug in clinical trials; this round of funding will go toward iterating the IsoDDE model, exploring new biological mechanisms, advancing internal proprietary pipelines, and building the partner ecosystem.
East MoneyRelated discussion
East Money joined this discussion
This post contributes to heat; it is not a formal report or confirmed fact.
36Kr · AI
Isomorphic Labs Completes $5 Billion Series C Funding
Isomorphic Labs, a UK-based AI drug discovery company founded by Demis Hassabis, announced the completion of a $5 billion Series C funding round, co-led by Greenoaks and Sequoia Capital, with Alphabet continuing to invest heavily. Together with its previous $600 million first external funding and $2.1 billion Series B, the company's publicly disclosed funding totals $7.7 billion. The new funds will be used to upgrade its drug design engine IsoDDE, expand its in-house and partnered drug candidate pipelines, and build global AI-driven bioengineering infrastructure.
SiliconANGLE
Alphabet's Isomorphic Labs Completes $5 Billion Funding Round to Accelerate Drug Discovery with AI
Isomorphic Labs announced the completion of a $5 billion funding round, led by Greenoaks and Sequoia Capital, with parent company Alphabet participating through GV and CapitalG. Its drug design platform IsoDDE uses AI to accelerate steps such as finding protein binding pockets, and claims it can skip the 3D protein modeling step required by the FEP algorithm while delivering higher-quality output. CEO Demis Hassabis said the funds will be used to build foundational biology models, deepen understanding of systemic diseases, and advance the first batch of therapeutic programs into clinical trials.
Nov 17
Peter Yang
Peter Yang reposted Demis Hassabis's announcement that Isomorphic Labs has raised $500 million in funding
Peter Yang reposted Demis Hassabis's announcement and expressed support, saying he is the right person to tackle disease. In the quoted tweet, Demis Hassabis announced that Isomorphic Labs has raised $500 million in funding to accelerate its goal of solving all disease, and said the team is using AI to reimagine drug design from first principles in order to drastically shorten the time and cost of new drug development.
The Decoder
Isomorphic Labs Completes $5 Billion Funding Round, Its Second in Six Months
Isomorphic Labs, the Alphabet-owned AI drug discovery company, has completed a $5 billion funding round co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor and Alphabet and all existing investors participating. This is the company's second major funding round within six months, following a $2.1 billion raise in May 2026. The funds will be used to advance its proprietary IsoDDE (Isomorphic Drug Design Engine) platform and push its drug pipeline into clinical trials; the company says IsoDDE builds on AlphaFold 3 to further predict drug binding and docking sites. Isomorphic Labs was founded in 2021 and has partnerships with Novartis, Eli Lilly, and Johnson & Johnson, and currently has no approved drugs.
TechCrunch AI
Isomorphic Labs Completes $5 Billion Series C Funding to Advance Drug Candidates into Clinical Trials
Isomorphic Labs, the AI drug discovery platform spun out of Google DeepMind, has completed a $5 billion Series C funding round, co-led by Greenoaks and Sequoia Capital, with participation from existing investors including Andreessen Horowitz and Alphabet's GV and Capital G. The company says its AlphaFold-based AI drug design engine has achieved positive preclinical results in oncology and immunology, and it has partnerships with Eli Lilly, Novartis, and Johnson & Johnson. The funding will be used to continue developing the drug design engine and expand into more drug types. The company did not disclose its latest valuation; Bloomberg previously reported that it was seeking funding at a $50 billion valuation.
CNBC Technology
Demis Hassabis-founded Isomorphic Labs completes $5 billion Series C funding round
Isomorphic Labs has completed a $5 billion Series C funding round, co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and funding from Alphabet as well. The funds will be used to design and develop new drugs with AI, advancing foundational biology models, disease understanding, and the first batch of therapeutic programs into clinical trials. This round comes about three and a half months after Hassabis stepped down as CEO of Google DeepMind; the company's previous round was a $2.1 billion Series B in May; according to Dealroom, drug discovery startups raised a cumulative $23.2 billion in 2026, setting a record.
Zhidx
Isomorphic Labs Completes $5 Billion Series C Funding
Isomorphic Labs, a UK-based AI drug discovery company founded by Demis Hassabis, co-founder of Google DeepMind, announced the completion of a $5 billion Series C funding round, co-led by Greenoaks and Sequoia Capital, with Alphabet continuing to invest heavily. Together with its previous $600 million first external financing and $2.1 billion Series B round, the company's publicly disclosed funding totals $7.7 billion. The new funds will be used to upgrade its proprietary drug design engine IsoDDE, expand its self-developed and partnered drug candidate pipelines, and build global AI-driven bioengineering infrastructure.
Phoenix Technology
Isomorphic Labs Completes $5 Billion Series C Funding
Isomorphic Labs, an AI drug discovery company founded by DeepMind co-founder Hassabis, has announced the completion of a $5 billion Series C funding round, co-led by Greenoaks and Sequoia Capital, with Alphabet continuing to invest heavily. Together with its earlier $600 million first external financing and $2.1 billion Series B, the company's publicly disclosed funding totals $7.7 billion. The new funds will be used to upgrade its drug design engine IsoDDE, expand its in-house and partnered drug candidate pipelines, and build global AI-driven bioengineering infrastructure; its internal oncology and immunology programs and partnered projects have achieved positive preclinical results and are preparing to enter clinical trials.
Tech.eu
Isomorphic Labs Completes $5 Billion Series C Funding, Co-led by Sequoia and Greenoaks
Isomorphic Labs has completed a $5 billion Series C funding round, co-led by Greenoaks and Sequoia, with participation from Andreessen Horowitz, Thrive Capital, Alphabet and its GV, CapitalG, Tamesek and the Sovereign AI fund. This comes just six months after its $2.1 billion Series B funding round. The London-based company, spun out of Google DeepMind and founded by Demis Hassabis, conducts drug discovery based on technologies such as AlphaFold and is expanding its proprietary drug design engine IsoDDE and its pipeline of AI-designed drug candidates, with the funds to be used to advance the drug candidates into clinical trials.
Unite.AI
Isomorphic Labs Completes $5 Billion Series C Financing to Advance AI Drug Design
On November 17, 2026, Isomorphic Labs announced the completion of a $5 billion Series C financing round, co-led by Greenoaks and Sequoia Capital. The funds will be used to continue developing its proprietary drug design engine IsoDDE, expand into new biological domains, and build global AI bioengineering infrastructure, while also establishing translational and clinical development capabilities to advance candidate drugs into clinical trials. Previously, the company completed a $2.1 billion Series B round led by Thrive Capital in May 2026, and a $600 million first external financing round in March 2025.
Testing Catalog
Isomorphic Labs Completes $500 Million Series C Funding
Isomorphic Labs, the AI drug discovery company founded by Demis Hassabis, has completed a $500 million Series C funding round. Investors include Greenoaks, Sequoia Capital and Andreessen Horowitz, with Alphabet continuing to participate. The company focuses on using AI to design and develop new drugs. Demis Hassabis said this will accelerate its mission to tackle diseases and reduce the time and cost required to discover new medicines.
Demis HassabisSelected
Demis Hassabis announces Isomorphic Labs has raised $500 million in funding
Demis Hassabis announced that Isomorphic Labs has raised $500 million in funding to accelerate its goal of "solving all diseases." He said the team is using AI to redesign drugs from first principles in order to drastically shorten the time and cost of new drug development.
Heat trend for this story
- Current
- 90
- Period peak
- 133 Nov 18 16:00
- 24-hour change
- +1%
Move the pointer or select the chart to inspect hourly heat. Use the left and right arrow keys with a keyboard.
AI Trends